The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target
Open accessAbstract
Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“This process has a higher efficiency than the formation of secondary metastases as the neovasculature is leaky at the primary tumour, and there is no need to adapt to the new microenvironment [Carmeliet and Jain, 2000].”
BackgroundMolecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620 · cited 1×
“The interaction of the Notch ligands, Delta-like and Jagged, with Notch receptors on neighbouring cells, causes a cleavage of the transmembrane receptor, resulting in the release of the Notch intracellular domain allowing trans- location to the nucleus [Bray, 2006; Miele, 2006].”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 2×
“…161Cells Tissues Organs 2022;211:157–182 DOI: 10.1159/000512218 not gain expression of ABC transporters and no longer have an increased drug efflux [Singh and Settleman, 2010; Du and Shim, 2016], which would increase the efficacy of classical chemotherapy [Meidhof et al., 2015; Zhou et al., 2015].”
BackgroundInfluentialCancer Invasion and the Microenvironment: Plasticity and Reciprocity
Friedl, P., & Alexander, S. (2011) · Cell · doi:10.1016/j.cell.2011.11.016 · Cited by 1,940
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 1×
“However, such in vitro studies still lack many biological elements present in vivo that are potentially key in promoting tumour progression, dissemination, and re-epithelialisation – for example, the immune system and the surrounding vasculature [De Palma et al., 2017; Janssen et al., 2017].”
BackgroundDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Wnt signal transduction pathways
Komiya, Y., & Habas, R. (2008) · Organogenesis · doi:10.4161/org.4.2.5851 · Cited by 1,528
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
NF-κB, an Active Player in Human Cancers
Xia, Y., Shen, S., & Verma, I. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0112 · Cited by 1,213 · cited 2×
“As such, the NF-κB pathway not only plays a critical role by protecting the transformed cells from apoptosis [Xia et al., 2014; Xia et al., 2018], but also promotes EMT leading to increased invasiveness of many different cancer types [Helbig et al.”
BackgroundCancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910 · cited 1×
“CSCs or tumourinitiating cells are a subpopulation of cancer cells displaying characteristics of normal stem cells, such as the potential to self-renew, driving tumour growth, and the formation of secondary tumours [Yu et al., 2012; Ayob and Ramasamy, 2018].”
BackgroundModelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Specificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785 · cited 1×
“The best-known inducer of EMT is TGF-β [Thiery et al., 2009; Fabregat et al., 2014; Lamouille et al., 2014; Zarzynska, 2014], a multifunctional cytokine belonging to a larger family of structurally and functionally related proteins including activins/inhibins and the BMPs [Derynck and Budi, 2019].”
BackgroundHelbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Non-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
Syed, V. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25496 · Cited by 482
The mouse ascending: perspectives for human-disease models
Rosenthal, N., & Brown, S. (2007) · Nature Cell Biology · doi:10.1038/ncb437 · Cited by 442
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395
Poltavets, V., Kochetkova, M., Pitson, S. M., & Samuel, M. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00431 · Cited by 377
Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails
Legate, K. R., & Fässler, R. (2009) · Journal of Cell Science · doi:10.1242/jcs.041624 · Cited by 370
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
Pattabiraman, D. R., Bierie, B., Kober, K. I., Thiru, P., Krall, J. A., Zill, C., Reinhardt, F., Tam, W. L., & Weinberg, R. A. (2016) · Science · doi:10.1126/science.aad3680 · Cited by 332
Lazzari, G., Nicolas, V., Matsusaki, M., Akashi, M., Couvreur, P., & Mura, S. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.008 · Cited by 271
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Maier, H. J., Schmidt-Straßburger, U., Huber, M. A., Wiedemann, E. M., Beug, H., & Wirth, T. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.003 · Cited by 215
Nowarski, R., Jackson, R., & Flavell, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.040 · Cited by 191 · cited 2×
“…relevant for screenings targeting EMT, which has been shown to be highly influenced by cues that are absent in 2D cultures, such as the ECM [Poltavets et al., 2018], host stromal cells [Nowarski et al., 2017], and the mechanical environment [Nasrollahi and Pathak, 2016; Shellard and Mayor, 2019].”
BackgroundDevelopmental capacities of benign and malignant neoplasms ofDrosophila
Gateff, E., & Schneiderman, H. A. (1974) · Wilhelm Roux Archiv f�r Entwicklungsmechanik der Organismen · doi:10.1007/bf00577830 · Cited by 143
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
Cited by
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Huang, Y., Hong, W., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01347-8 · Cited by 1,032
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Epithelial–mesenchymal transition and its transcription factors
Debnath, P., Huirem, R. S., Dutta, P., & Palchaudhuri, S. (2022) · Bioscience Reports · doi:10.1042/bsr20211754 · Cited by 281
Xie, Y., Wang, X., Wang, W., Pu, N., & Liu, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06422-5 · Cited by 80
“Current strategies for targeting EMT include: (i) inhibition of upstream signaling pathways (TGF-β, NF-κB, EGFR, c-MET, WNT, and Notch signaling), (ii) suppression of EMT-TFs, (iii) targeting mesenchymal characteristics (as summarized in previous reviews [158, 159]).”
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
Metadata
- Authors
- Jonckheere, S., Adams, J., De Groote, D., Campbell, K., Berx, G., & Goossens, S.
- Venue
- Cells Tissues Organs
- Publisher
- S. Karger AG
- Published
- 2021-01-05
- Volume
- 211
- Issue
- 2
- Pages
- 157-182
- ISSN
- 1422-6405 (ISSN-L)
- 1422-6421
- OpenAlex
- W3119305305
- Cited by
- 171
- References
- 29
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.